anes and the 4 series leukotrienes (LTs). Arachidonic acid is also converted into non-enzymatic lipid mediators -4-hydroxynonenal, isoprostanes, isoketals and isofurans -in tissues by free radicals in vivo and are useful as markers for oxidative stress.
Similar to w-6 LA, w-3 ALA is converted to eicosapentaenoic acid (EPA, 20:5, w-3) by D 6 and D 5 desaturases, the precursor of the 3 series of prostaglandins and the 5 series of LTs. Eicosapentaenoic acid can be elongated to form docosahexaenoic acid (DHA, 22:6, w-3). The AA, EPA and DHA also give rise to anti-inflammatory lipoxins: resolvins, protectins and maresins [2] [3] [4] [5] [6] [7] [8] [9] [10] [11] (see Figure 1 for metabolism of EFAs and the formation of lipoxins and resolvins). Eicosanoids bind to G protein-coupled receptors and mediate many steps of inflammation [7] [8] [9] [10] . Non-steroidal anti-inflammatory drugs (NSAIDs) such as aspirin inhibit cyclo-oxygenase (COX) activity and thus bring about their anti-inflammatory action.
The general purpose of lipoxins and similar compounds generated from AA, EPA and DHA is not only to suppress the production of pro-inflammatory prostaglandins, thromboxanes, leu- kotrienes and isoprostanes but also to limit inflammation, enhance wound healing and resolve inflammation and thus restore cell function to normal. Hence, when the formation of lipoxins, resolvins, protectins and maresins is defective or subnormal, it could lead to persistent inflammation and tissue injury [6] . This implies that increased formation of lipoxins, resolvins, protectins and maresins protects various cells including endothelial cells against the cytotoxic action of interleukin-6 (IL-6), tumor necrosis factor-α (TNF-α) and free radicals.
In this context, it is interesting to note that the beneficial effects of aspirin can be related to its inhibitory action on the enzyme cyclooxygenase (COX-2) and consequently a decrease in the production of pro-inflammatory prostaglandins (PGs), thromboxanes (TXs) and leukotrienes (LTs). It is noteworthy that aspirin does not interfere with the production of PGI2 but decreases the production of TXA2. In addition to inhibiting COX-2 activity, aspirin can also inhibit pro-inflammatory signaling pathways, gene expression and other factors distinct from eicosanoid biosynthesis that drive inflammation as well as enhance the synthesis of endogenous protective anti-inflammatory factors. Recent studies showed that aspirin induces the production of NO, which inhibits leukocyte/endothelium interaction during acute inflammation. Aspirin has the unique ability to acetylate the active site of inducible cyclooxygenase (COX-2), a property not shared with other NSAIDs, and generate the anti-inflammatory lipid mediators lipoxins (so-called aspirin-triggered epi-lipoxins), compounds that have profound roles in a range of host defense responses [12] . It was reported that a single anti-inflammatory dose of aspirin caused high levels of nitrite/nitrate to appear in the peripheral blood of the treated animals after a few hours. It was noted that a reduction in local inflammation correlated inversely with a dose-dependent and significant increase in plasma NO levels [13] . Further studies revealed that inhibiting aspirin-elicited NO nullified the anti-inflammatory effects of aspirin. Moreover, aspirin was not anti-inflammatory in either constitutive (eNOS) or inducible NO synthase (iNOS) knockout mice with IL-1β-induced peritonitis. It was found that aspirin generated NO through its unique ability to trigger the synthesis of 15-epi-lipoxin A4. Aspirin and 15-epi-lipoxin A4 inhibited leukocyte trafficking in an NO-dependent manner. Both aspirin and 15-epi-lipoxin A4 markedly reduced effects on leukocyte-endothelial cell adherence in eNOS-and iNOS-deficient mice compared with wild type. This evidence led to the conclusion that aspirin acetylates COX 2 within the endothelium or circulating leukocytes to trigger 15-epi-lipoxin A4, which, in turn, elicits NO synthesis from both eNOS and iNOS. It is this aspirin-triggered NO that mediates the anti-inflammatory effects of aspirin in the microcirculation [13] . These results imply that one of the factors that regulate the production of NO is LXA4. This is supported by the observation that the phosphodiesterase-III inhibitor cilostazol augments the infarct size (IS)-limiting effects of MK0626 (MK), a dipeptidyl-peptidase-4 (DPP4) inhibitor, by increasing intracellular cAMP in mice with type-2 diabetes. MK and cilostazol additive IS-limiting effects in diabetic mice were found to be associated with an increase in myocardial cAMP levels and protein kinase A (PKA) activity with downstream phosphorylation of Akt, eNOS, 5-lipoxygenase and CREB and downregulation of PTEN expression. It was shown that PKA phosphorylates 5-lipoxygenase at ser523, leading to increased production of 15-epi-lipoxin A4 [14] [15] [16] .
Based on these results [12] [13] [14] [15] [16] , I suggest that the beneficial actions of PDE-5-Is shown by ElSayed and Amin [1] are, at least in part, due to increased formation of LXA4 and, possibly, resolvins, protectins and maresins. This proposal could be verified by measuring plasma and tissue levels of LXA4 in those experimental animals and humans treated with sildenafil, vardenafil and tadalafil. This also implies that deficiency of AA, EPA and DHA (as would occur in EFA-deficient states) could interfere with the beneficial actions of sildenafil, vardenafil and tadalafil due to reduced formation of LXA4, resolvins, protectins and maresins. In addition, it is known that LXA4 has potent anti-nociceptive action similar to PDE-5-Is [17] [18] [19] . Based on the preceding discussion, it is concluded that further research is needed to confirm the role of LXA4, resolvins, protectins and maresins as one of the mechanisms of action of PDE-5-Is under different (patho)physiological conditions.
